A phase II trial of a personalized, dose-intense administration schedule of 177lutetium-dotatate in children with primary refractory or relapsed high-risk neuroblastoma-LuDO-N - Sundquist, F; Georgantzi, K; Jarvis, K B (Front Pediatr, 2022)